The Japan Genomic Medicine market reached US$ XX million in 2024 and is expected to reach US$ XX million by 2033, growing at a CAGR of XX% during the forecast period 2025-2033.
Genomic medicine is a field that uses a person’s genetic information to diagnose, treat, and prevent diseases. By analyzing DNA and genes, healthcare providers can identify genetic variations that influence health, such as susceptibility to diseases or how a person responds to certain medications. This allows for more personalized and precise treatments, improving outcomes and reducing side effects.
The applications of genomic medicine are broad, particularly in oncology, cardiology, and rare genetic disorders. In oncology, genomic testing helps identify mutations in cancer cells, enabling targeted therapies that are more effective. In cardiology, it can uncover genetic risk factors for heart disease, allowing for early interventions. Additionally, genomic medicine is crucial in diagnosing rare genetic disorders and customizing drug treatments based on a patient’s genetic profile, ensuring better efficacy and safety.
Market Dynamics: Drivers & Restraints
Growing demand for personalized medicine
The growing demand for personalized medicine is expected to play a significant role in driving the genomic medicine market. By tailoring treatment plans based on an individual’s genetic makeup, personalized medicine offers a more targeted approach to healthcare. As people become more aware of how genetics influence disease risk and drug responses, both patients and healthcare providers are looking for more effective, individualized treatments. Personalized medicine uses genomic data to identify mutations, assess disease risk, and design treatment plans that improve outcomes and minimize side effects.
As technologies like next-generation sequencing (NGS), biomarker discovery, and genetic testing advance, personalized medicine is becoming more accessible, particularly in areas such as oncology, rare genetic diseases, and cardiovascular conditions. This shift toward more personalized care is driving the growth of the genomic medicine market, as it offers more precise and effective healthcare solutions.
As personalized medicine continues to gain traction, technologies like this PCR system play a crucial role in advancing the ability to offer targeted, patient-specific healthcare solutions, contributing to the overall growth of the genomic medicine market.
High Costs of Genomic Testing and Treatments
The high costs associated with genomic testing and treatments are expected to be a significant hindrance to the growth of the genomic medicine market. Advanced genomic technologies, such as next-generation sequencing (NGS), can be expensive, with the costs of tests, equipment, and specialized personnel adding up.
Segment Analysis
The Japan genomic medicine market is segmented based on product type, technology, application, and end-user.
Product Type:
Oncology segment is expected to dominate the Japan genomic medicine market share
The oncology segment is dominating the genomic medicine market in Japan due to the country's high cancer incidence, aging population, and increasing demand for personalized cancer therapies. Advances in targeted therapies, immunotherapies, and early detection methods, such as liquid biopsy and next-generation sequencing (NGS), are central to this growth.
Japan’s strong regulatory support for precision medicine, along with collaborations between pharmaceutical companies, academia, and healthcare providers, further accelerates the adoption of genomic medicine in oncology. With a focus on improving treatment outcomes through genetic profiling, personalized care, and the development of innovative cancer therapies, genomic medicine is poised to revolutionize oncology in Japan, offering more tailored and effective treatment options for patients.
Competitive Landscape
The major players in Japan genomic medicine include RIKEN GENESIS CO., LTD., Chugai Pharmaceutical Co., Ltd., Illumina, Inc., QIAGEN, Agilent Technologies, Inc., Thermo Fisher Scientific Inc., Oxford Nanopore Technologies plc., Takara Bio Inc, and Eurofins Scientific among others.
Why Purchase the Report?
• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.
The Japan Genomic Medicine Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.
Target Audience 2023
• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.
- 1. Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
- 2. Definition and Overview
- 3. Executive Summary
- 3.1. Snippet by Product Type
- 3.2. Snippet by Technology
- 3.3. Snippet by Application
- 3.4. Snippet by End-User
- 4. Dynamics
- 4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.1.1. Growing demand for personalized medicine
- 4.1.2. Restraints
- 4.1.2.1. High Costs of Genomic Testing and Treatments
- 4.1.3. Opportunity
- 4.2. Impact Analysis
- 5. Strategic Insights and Industry Outlook
- 5.1. Market Leaders and Pioneers
- 5.1.1. Emerging Pioneers and Prominent Players
- 5.1.2. Established leaders with largest selling Brand
- 5.1.3. Market leaders with established Product
- 5.2. CXO Perspectives
- 5.3. Latest Developments and Breakthroughs
- 5.4. Case Studies/Ongoing Research
- 5.5. Regulatory and Reimbursement Landscape
- 5.6. Porter’s Five Force Analysis
- 5.7. Supply Chain Analysis
- 5.8. Patent Analysis
- 5.9. SWOT Analysis
- 5.10. Unmet Needs and Gaps
- 5.11. Recommended Strategies for Market Entry and Expansion
- 5.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
- 5.13. Pricing Analysis and Price Dynamics
- 5.14. Key Opinion Leaders
- 6. By Product Type
- 6.1. Introduction
- 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 6.1.2. Market Attractiveness Index, By Product Type
- 6.2. Kits & Reagents*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 6.3. Instruments and Equipment
- 6.4. Others
- 7. By Technology
- 7.1. Introduction
- 7.1.1. Analysis and Y-o-Y Growth Analysis (%), By Technology
- 7.1.2. Market Attractiveness Index, By Technology
- 7.2. Next-Generation Sequencing (NGS)*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Polymerase Chain Reaction (PCR)
- 7.4. Microarray
- 7.5. Gene Editing
- 7.6. Bioinformatics
- 7.7. Others
- 8. By Application
- 8.1. Introduction
- 8.1.1. Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.1.2. Market Attractiveness Index, By Application
- 8.2. Oncology*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Cardiology
- 8.4. Paediatrics
- 8.5. Endocrinology
- 8.6. Infectious Diseases
- 8.7. Others
- 9. By End-User
- 9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.1.2. Market Attractiveness Index, By End-User
- 9.2. Hospitals & Clinics*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Academic Institutions
- 9.4. Research Institutions
- 10. Competitive Landscape
- 10.1. Competitive Scenario
- 10.2. Market Positioning/Share Analysis
- 10.3. Mergers and Acquisitions Analysis
- 11. Company Profiles
- Key Market Players
- 11.1. RIKEN GENESIS CO., LTD.*
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio
- 11.1.2.1. Product Description
- 11.1.2.2. Product Key Performance Indicators (KPIs)
- 11.1.2.3. Historic and Forecasted Product Sales
- 11.1.2.4. Product Sales Volume
- 11.1.3. Financial Overview
- 11.1.3.1. Company Revenue’s
- 11.1.3.2. Geographical Revenue Shares
- 11.1.3.3. Revenue Forecasts
- 11.1.4. Key Developments
- 11.1.4.1. Mergers & Acquisitions
- 11.1.4.2. Key Product Development Activities
- 11.1.4.3. Regulatory Approvals etc.
- 11.1.5. SWOT Analysis
- 11.2. Chugai Pharmaceutical Co., Ltd.
- 11.3. Illumina, Inc.
- 11.4. QIAGEN
- 11.5. Agilent Technologies, Inc.
- 11.6. Thermo Fisher Scientific Inc.
- 11.7. Oxford Nanopore Technologies plc.
- 11.8. Takara Bio Inc
- 11.9. Eurofins Scientific
- * Similar data will be provided for each market player.
- LIST NOT EXHAUSTIVE
- 12. Appendix
- 12.1. About Us and Services
- 12.2. Contact Us
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook